Published in Oncology Business Week, July 23rd, 2006
This trial is being sponsored by the National Cancer Institute (NCI) under a Clinical Trials Agreement with CuraGen for the clinical development of PXD101.
The Phase II clinical trial is an open-label study being led by Suresh Ramalingam, MD, assistant professor of medicine at the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania. Patients with unresectable malignant pleural...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week